Login to Your Account

Same Questions Dog Others In Race

Momenta's Trials May Continue As FDA Slows Generic Lovenox

By Randall Osborne

Monday, November 12, 2007
The FDA's stance on generics - at least on versions of the blood thinner Lovenox, such as Momenta Pharmaceuticals Inc.'s M-Enoxaparin (and probably similar compounds from Teva Pharmaceuticals Industries Ltd. and Amphastar Pharmaceuticals Inc. - became somewhat clearer last week, sadly and surprisingly for hanging-on Momenta investors who watched the stock's value tumble 58 percent, closing at $5.67. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription